BCR-Abl tyrosine kinase inhibitor Nilotinib (Tasigna®) reverses ABCB1/Pgp- and ABCG2/BCRP-mediated multidrug resistance Conference Poster (Faculty180)

cited authors

  • Tiwari, Amit K; Sodani, K; Wang, S; Kuang, Y H; Chen, X; Chen, K; Ashby, Charles Jr; Chen, Z S

publication date

  • 2010

presented at event